In the present study, we investigated the effect of CDK inhibitors (ribociclib, palbociclib, seliciclib, AZD5438, and dinaciclib) on malignant human glioma cells for cell viability, apoptosis, oxidative stress, and mitochondrial function using various assays.
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In the present study, we investigated the effect of CDK inhibitors (ribociclib, palbociclib, seliciclib, AZD5438, and dinaciclib) on malignant human glioma cells for cell viability, apoptosis, oxidative stress, and mitochondrial function using various assays.
None of the CDK inhibitors induced cell death at a clinically relevant concentration.
However, low nanomolar concentrations of dinaciclib showed higher cytotoxic activity against Bcl-xL silenced cells in a time-and concentration-dependent manner. This effect was not seen with other CDK inhibitors. The apoptosis-inducing capability of dinaciclib in Bcl-xL silenced cells was evidenced by cell shrinkage, mitochondrial dysfunction, DNA damage, and increased phosphatidylserine externalization. Dinaciclib was found to disrupt mitochondrial membrane potential, resulting in the release of cytochrome c, AIF, and smac/DIABLO into the cytoplasm. This was accompanied by the downregulation of cyclin-D1, D3, and total Rb. Dinaciclib caused cell cycle arrest in a time-and concentration-dependent manner and with accumulation of cells in the sub-G1 phase. Our results also revealed that dinaciclib, but not ribociclib or palbociclib or seliciclib or AZD5438 induced intrinsic apoptosis via upregulation of the levels of pro-apoptotic proteins (Bax and Bak), resulting in the activation of caspases and cleavage of PARP. We also found an additional mechanism for the dinaciclib-induced augmentation of apoptosis due to abrogation RAD51-cyclin D1 interaction, specifically proteolysis of the DNA repair proteins RAD51 and Ku80. Our results suggest that successfully interfering with Bcl-xL function may restore sensitivity to dinaciclib and could hold the promise for an effective combination therapeutic strategy.
transition of the cell cycle, is disrupted in the vast majority of human malignant gliomas and leads to dysregulated cell cycle progression.
Common genomic alterations include homozygous deletion of CDKN2A/2B (52%), amplification of CDK4 (18%), amplification of CDK6 (1%), and deletion or mutation of RB (12%). 1 Given the central role of cyclin-D/CDK4/RB pathway in cell cycle control, it has been hypothesized that targeting CDKs may have broad antitumor activity in human malignancies. Although administration of flavopiridol exhibited some clinical activity in hematological malignancies, 6 phase II clinical studies showed poor efficacy for solid tumors.
Similarly, seliciclib (roscovitine) failed to produce antitumor activity both in preclinical and clinical studies as monotherapy. Because the first-generation pan-CDK inhibitors suffered from a low therapeutic index, second-generation pan-CDK inhibitors were developed; such as ribociclib, palbociclib, AZD5438, and dinaciclib to name a few.
Ribociclib (LEE011, Novartis) selectively inhibits CDK4 and CDK6 at a low nanomolar concentration. It inhibits RB phosphorylation and causes cell cycle arrest. 7 Ribociclib has shown efficacy in xenograft experimental models of neuroblastoma, 7 rhabdomyosarcoma 8 and is currently being evaluated in many clinical trials. 9 Palbociclib (PD0332991, Pfizer) inhibits both CDK4 and CDK6 kinase activity, prevents RB phosphorylation and induces cell cycle arrest and antitumor activity in glioma. 10 Michaud et al 11 demonstrated that systemic administration of palbociclib crossed the blood-brain barrier in an orthotopic xenograft model of glioblastoma. AZD5438 (Astra Zeneca, Boston, MA) is an orally bioavailable inhibitor of cyclin E-CDK2, cyclin A-CDK2, and cyclin B-CDK1 complexes with a promising clinical efficacy profile. 12 However, a post hoc analysis of patients treated with AZD5438 showed a poorer outcome. 13 Dinaciclib (SCH 727965/ MK-7965; Merck & Co., Kenilworth, NJ), inhibits CDK1, 2, 5, 9, and RB phosphorylation and entered phase 2 and 3 clinical trials.
Multiple studies in several cancer types demonstrated modest singleagent clinical activity. 14, 15 In a recent study, we observed that the effects of ribociclib, palbociclib, AZD5438, and dinaciclib were principally cytostatic rather than cytotoxic in glioma cell lines. 16 We also observed that only dinaciclib but not ribociclib, palbociclib, seliciclib, or AZD5438 had significant proapoptotic effects on glioma when combined with ABT737 (Bcl2/Bcl-xL inhibitor), thus providing a rationale for further evaluation.
Through siRNA screening, we were able to identify the critical anti-apoptotic proteins, including Bcl-xL, that when inhibited, greatly promoted apoptotic signaling in glioma cells. [16] [17] [18] [19] [20] [21] [22] We hypothesized that the functional blockade of Bcl-xL should sensitize these glioma cells to CDK inhibitors by restoring the apoptotic process. Because targeting BCL-2 family members with small molecules is challenging, 23 and most of the BH3 mimetics bind their targets with poor affinity and induce cell death independently from the mitochondrial apoptotic pathway, in this study, we used lentiviral-based RNA interference to silence Bcl-xL function (genetic inhibition) to examine the impact on efficacy of CDK inhibitors. Our study suggests that low nanomolar concentrations of dinaciclib induced loss of mitochondrial membrane potential and caused a conformational change in proapoptotic molecules Bax and Bak, initiating cytochrome c release and caspase activation that resulted in cell death. We also demonstrated a unique mechanism linking DNA damage response to cell death.
| MATERIALS AND METHODS

| Cell lines
The malignant human glioma cell line U87 was obtained from the American Type Culture Collection (Manassas, VA). LNZ308 was provided by Dr. Nicolas de Tribolet (Lausanne, Switzerland). Cell culture conditions of these cell lines were as previously described. 16 Cell lines used in this study were authenticated using Short Tandem
Repeat (STR) analysis by ATCC cell line authentication service (Manassas, VA). Samples were processed using the ABI Prism® 3500xl Genetic Analyzer and data was analyzed using GeneMapper ® ID-X v1.2 software (Applied Biosystems, Foster City, CA). The genetic profiles for the samples were identical to the reported profile.
| Reagents and antibodies
Ribociclib, palbociclib, AZD5438, and dinaciclib were from Selleck (Houston, TX). All other chemicals used in this study were from Sigma (St. Louis, MO). The following antibodies were used: β-actin 
| Stable cell line generation
Bcl-xL and non-target control shRNA MISSION Lentiviral transduction particles used in this study were obtained from Sigma. LNZ308 and U87 human glioma cells were seeded in six-well plates and allowed to reach 70-80% confluence and infected according to the manufacturer's recommendations (Sigma). The day after infection, medium was changed and cells were incubated with complete media containing puromycin (1 μg/mL). After 14 days, cell extracts were separated by SDS-PAGE and subjected to Western blotting analysis with Bcl-xL antibody.
| Annexin V apoptosis assay
Apoptosis induction in vehicle-or inhibitor-treated cells was assayed by the detection of membrane externalization of phosphatidylserine using an Annexin V assay kit (Molecular Probes, Invitrogen, Carlsbad, CA) as described previously. 24 PI staining provides a measure of cell viability and is used to distinguish between cells in early and late apoptosis.
| DiOC6 labeling and detection of mitochondrial membrane depolarization
Mitochondrial membrane depolarization was measured as described previously. 22 In brief, floating cells were collected, and attached cells 
| Determination of reactive oxygen species generation
Reactive oxygen species (ROS) production was monitored with the 25 The functional role of ROS generation on apoptosis was assessed in additional experiments using the free radical scavenger N-acetyl-l-cysteine (NAC). Cells were pre-incubated with 5 mM NAC for 2 h, followed by co-incubation with inhibitors and assessment of apoptosis or ROS generation as described above.
| Cell cycle analysis
The effect of varying concentrations of inhibitors on cell cycle distribution was determined by flow cytometric analysis of the nuclear DNA content as previously described. 26 Briefly, cells grown exponentially to 50-60% confluency were exposed to the inhibitors or DMSO for a range of intervals, harvested, washed in ice-cold PBS, and fixed in Lysates were clarified by centrifugation at 15 000g for 10 min at 4°C, and the protein concentrations in the supernatants were determined.
| Immunoprecipitation and western blotting analysis
Equal amounts of protein extracts were incubated overnight with primary antibody (active Bax, 6A7, Sigma or active Bak, 1Ab).
Afterward, Dynabeads Protein G (Invitrogen) was added for 2 h, followed by magnetic separation of the immunoprecipitated fraction;
Western blot analysis was carried out as described above.
Scanning densitometry was performed on Western blots using acquisition into Adobe Photoshop (Adobe Systems, Inc., San Jose, CA)
followed by image analysis (UN-SCAN-IT gel TM, version 6.1, Silk
Scientific, Orem, UT). Values in arbitrary numbers shown in the
Western blots represent densitometer quantification of bands normalized to loading control.
| Subcellular fractionation
Cells were treated with or without inhibitors and cytosolic proteins were fractionated as described previously. 22, 27 Briefly, cells were resuspended in a lysis buffer containing 0.025% digitonin, sucrose following the manufacturer's instructions.
| Transient transfection
Sequence-specific ON-TARGETplus siRNA for human RAD51 (catalog 
| Fluorescence microscopy
Cells were grown on chamber slides (Nalge Nunc, Naperville, IL) in growth medium, and, after an overnight attachment period, were exposed to selected concentrations of dinaciclib or vehicle (DMSO) for various intervals. 
| Statistical analysis
Unless otherwise stated, data are expressed as mean ± S.D. The significance of differences between experimental conditions was determined using a two-tailed Student's t test. Differences were considered significant at P values <0.05.
| RESULTS
| Bcl-xL silencing causes an increase in cell death induced by nanomolar concentrations of dinaciclib
We and others have shown that CDK inhibitors induce cell death by antagonizing the activity of antiapoptotic Bcl-2 family proteins. 16, 28 In this study, we examined whether Bcl-xL, which is frequently overexpressed in glioma, is associated with resistance to CDK inhibitors. To experimentally address this question, we generated stable cell lines depleted of Bcl-xL or 
| Low concentrations of dinaciclib induce mitochondrial dysfunction in Bcl-xL silenced cells
Apoptosis may be initiated by signaling at the plasma membrane or by intracellular pathways that lead to changes in mitochondria. 29 Because
Bcl-xL is predominantly located in the mitochondria and regulates mitochondrial energetics by stabilizing the membrane potential, 30 we hypothesize that CDK inhibitors may cause mitochondrial dysfunction.
Both non-target shRNA and Bcl-xL shRNA-transduced cells were treated with CDK inhibitors at the indicated concentrations, and mitochondrial membrane potential loss (Δψm) was analyzed by flow cytometry using Because loss of mitochondrial membrane potential can trigger a cascade of downstream events to initiate apoptosis, including the activation of caspases resulting in cell death, 32 we examined the activation/cleavage of pro-caspase-9 and pro-capsase-8, which activates intrinsic and extrinsic apoptosis pathways, respectively, culminating in the cleavage of executioner caspase-3, caspase-7, and PARP. Silencing of Bcl-xL enhanced dinaciclib-induced caspase and PARP activation in a concentration ( Figure 4C ) and time ( Figure 4D ) dependent manner.
| Dinaciclib induces ROS generation in Bcl-xL depleted cells
Because Figure 5D ). However, pretreatment with NAC significantly protected cells from dinaciclibinduced cell death ( Figure 5C ) and loss of mitochondrial membrane potential ( Figure 5D ).
| Dinaciclib downregulates cell cycle regulatory proteins in Bcl-xL depleted cells
Because dinaciclib demonstrated strong selectivity to inhibit cell proliferation and to induce apoptosis in Bcl-xL silenced cells, we examined the impact of this agent on cell cycle regulatory proteins.
As shown in Figures 6A and 6B , dinaciclib did not alter CDK2, CDK4, CDK6, and CDK9, cyclin B1, cyclin D1 and cyclin D3 protein levels in non-target shRNA-carrying LNZ308 ( Figure 6A left panel) and U87
( Figure 6B, left panel) , respectively. However, a significant reduction First, we examined phosphorylation of γ-H2AX, a sensitive marker for unrepaired double strand breaks 36, 37 which was shown to correlate with cell death. 38 Western blot analysis showed that dinaciclib caused increased levels of γ-H2AX phosphorylation in a time-dependent manner. Phosphorylation of γ-H2AX was more rapidly and robustly increased in Bcl-xL silenced cells than the non-target shRNA control cell lines (Figures 7A and 7B) . Similarly, at least 80% of Bcl-xL silenced U87 and LNZ308 cells had γ-H2AX foci compared to only 10% of nontarget control cells (Supplementary Figure S4) .
We then examined Ku70, Ku80, and RAD51, which enable the repair of DNA double strand breaks through the non-homologous end joining pathway. 39 As shown in Figures 7A and 7B , treatment with dinaciclib significantly reduced Ku70 protein levels. Interestingly, we observed the appearance of ∼18 kDa fragment in the Ku80 blot (cleaved form of Ku80) in a time-dependent manner in Bcl-xL silenced cells but not in non-target shRNA-carrying cells, suggesting that treatment with dinaciclib promotes proteolytic cleavage of Ku80 in Bcl-xL-silenced cells. We also observed that in addition to the fulllength RAD51 (molecular weight of 37 kDa), a 21 kDa cleaved fragment appeared after dinaciclib treatment ( Figures 7A and 7B ).
Then to confirm that Ku80 cleavage was prior to caspase activation, we treated cells with zVAD-fmk (pan caspase inhibitor) for 2 h before treatment with dinaciclib and analyzed by Western blotting. As shown in Figure 7C , dinaciclib-induced Ku80 cleavage was blocked by caspase inhibition.
Because RAD51 directly binds cyclin D1 and is recruited to DNA damage sites, 40 we hypothesized that Bcl-xL silencing would have a significant impact on the protein-protein interaction following dinaciclib treatment. Immunoprecipitation followed by Western blot analysis revealed that treatment with dinaciclib clearly reduced cyclin D1 and RAD51 interaction in Bcl-xL silenced cells ( Figure 7D ). Then, we looked at the intracellular distribution of RAD51. Immunofluorescence staining 
| DISCUSSION
Although the concept of pharmacological inhibition of CDK has scientific rationale, CDK inhibitors have shown poor clinical efficacy as single agents, possibly because of the multiplicity of targets that contribute to cell cycle regulation and cell survival. 9, 14, [42] [43] [44] In this report, we showed that glioma cells are resistant to ribociclib, palbociclib, seliciclib, AZD5438, and dinaciclib at concentrations well above the clinically achievable range to induce apoptosis in vitro.
However, disruption of Bcl-xL resulted in a marked increase in dinaciclib-induced cell death at low nanomolar concentrations.
Importantly, this effect was not seen with other CDK inhibitors.
Investigating the molecular mechanisms, we found that silencing Bcl-xL led to severe mitochondrial dysfunction and persistent DNA damage, suggesting a functional role for Bcl-xL which may translate dinaciclib into clinical relevance. Cell cycle analysis using propidium iodide (PI) staining was performed as described in the Section 2. Representative cell cycle FACS plots are shown here. Three independent experiments produced similar results 5.0 μmol/L). On the contrary, there was no impairment in mitochondrial function or the activation of caspases after ribociclib, palbociclib, and seliciclib treatments. In this context, Bax/Bak-induced damage of mitochondrial membranes could play an essential role in cell death.
Because dinaciclib-induced cell death but not loss of mitochondrial membrane potential could be blocked using the pan-caspase inhibitor zVAD-fmk, it was apparent that mitochondrial dysfunction constituted an upstream event of caspase activation. This observation is in agreement with our recent study involving pharmacological inhibition of Bcl-xL using ABT737 followed by dinaciclib treatment, which synergistically induced apoptosis in malignant human glioma cell lines. 16 Numerous reports have linked ROS with mitochondrial dysfunction,
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Continued. was identified as a cyclin D1 protein binding partner, 40 we also examined this interaction by immunoprecipitation analysis. Our study revealed that the dinaciclib treatment caused a reduction of cyclin D1/RAD51 association and could impair the recruitment of RAD51 to damaged DNA (as evidenced by lack of nuclear RAD51 after dinaciclib treatment), thus impeding homologous recombination-mediated DNA repair in Bcl-xL silenced cells.
Our results also demonstrated that treatment with dinaciclib resulted in proteolysis of Ku80. This was in agreement with Song et al, 63 where they have shown that Ku proteins were downregulated and cleaved by proteases under oxidative stress conditions. Their study also suggests that ROS played an important role in reducing the DNA repair activity by degrading Ku proteins.
Because several studies have implicated p53 in mediating differential responses to CDK inhibitors, [64] [65] [66] [67] [68] we used p53 wildtype (U87) and p53-deleted (LNZ308) cell lines and clearly demonstrated that the apoptotic response observed in this study was not influenced by p53 functional status. In summary, because a substantial amount of mitochondrial energy is required for cell-cycle progression, 69 we conclude that the loss of overall mitochondrial integrity and resultant DNA damage may contribute to the observed cell death in response to dinaciclib in Bcl-xL silenced cells. The concentrations of dinaciclib we evaluated were within the physiologically relevant/clinically achievable (82-184 nmol/L) range. 14, 43 Thus, successfully interfering with Bcl-xL function may promote sensitivity to dinaciclib.
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